Actively Recruiting
Impact of Metamizole Optalgin on Anti-Xa Levels in Adult Cancer Patients Using Direct Oral Anticoagulants
Led by Rambam Health Care Campus · Updated on 2026-02-03
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate how metamizole Optalgin affects Anti-Xa levels in cancer patients who are taking direct oral anticoagulants DOACs such as apixaban or rivaroxaban. The study focuses on oncology patients requiring anticoagulation and pain management, assessing the interaction between these medications to better understand their combined effects during cancer treatment. Participants are divided into two groups those who have been using metamizole chronically before joining the study and those who start metamizole treatment after enrollment. Both groups receive at least 1 gram of metamizole three times daily for pain relief while continuing their DOAC therapy. The study tracks changes in Anti-Xa concentrations at multiple time points, including baseline, end of treatment, and several days post treatment. During the study, researchers will monitor Anti-Xa levels to measure how the DOACs are affected by metamizole use. Patients will undergo blood tests at specified intervals to capture these changes. The study also ensures safety by excluding those with certain gastrointestinal issues or allergies to the medications. Participation involves providing informed consent and meeting health criteria, with the total duration and follow-up designed to observe effects up to seven days after treatment ends.
CONDITIONS
Brief Title
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Research Team
L
Liat Rappaport
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here